Last reviewed · How we verify
Vehicle of Ophthalmic Loteprednol Etabonate — Competitive Intelligence Brief
phase 3
corticosteroid
glucocorticoid receptor
Ophthalmology
Small molecule
Live · refreshed every 30 min
Target snapshot
Vehicle of Ophthalmic Loteprednol Etabonate (Vehicle of Ophthalmic Loteprednol Etabonate) — Bausch & Lomb Incorporated. Loteprednol etabonate is a corticosteroid that reduces inflammation by inhibiting the production of prostaglandins.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Vehicle of Ophthalmic Loteprednol Etabonate TARGET | Vehicle of Ophthalmic Loteprednol Etabonate | Bausch & Lomb Incorporated | phase 3 | corticosteroid | glucocorticoid receptor | |
| Durezol | DIFLUPREDNATE | Novartis | marketed | difluprednate | Glucocorticoid receptor | 2008-01-01 |
| Arnuity Ellipta | FLUTICASONE FUROATE | Haleon Us Holdings | marketed | Corticosteroid | Glucocorticoid receptor | 2007-01-01 |
| Omnaris | CICLESONIDE | Covis | marketed | ciclesonide | Glucocorticoid receptor | 2006-01-01 |
| Omnaris | Alvesco | Takeda Gmbh | marketed | ciclesonide | Glucocorticoid receptor | 2006-01-01 |
| Mifeprex | MIFEPRISTONE | Corcept Therap | marketed | Progestin Antagonist [EPC] | Glucocorticoid receptor | 2000-01-01 |
| Lotemax | LOTEPREDNOL ETABONATE | Bausch Health | marketed | Corticosteroid | Glucocorticoid receptor | 1998-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Omnaris · 8371292 · US
- — Lotemax · 9056057 · Formulation · US
- — Lotemax · 9532955 · Method of Use · US
- — Lotemax · 10058511 · Formulation · US
- — Lotemax · 11219596 · Method of Use · US
- — Lotemax · 11219597 · Method of Use · US
- — Lotemax · 11596599 · Method of Use · US
- — Lotemax · 10857096 · Method of Use · US
- — Lotemax · 10864219 · Method of Use · US
- — Lotemax · 10945948 · Method of Use · US
- — Lotemax · 10940108 · Method of Use · US
- — Lotemax · 9737491 · Method of Use · US
- — Lotemax · 9827191 · Formulation · US
- — Lotemax · 11872318 · Formulation · US
- — Lotemax · 9393213 · Formulation · US
- — Lotemax · 10646436 · Formulation · US
- — Lotemax · 10993908 · Method of Use · US
- — Lotemax · 12115246 · Formulation · US
- — Lotemax · 10688045 · Formulation · US
- — Lotemax · 11642317 · Formulation · US
- — Lotemax · 10646437 · Formulation · US
- — Lotemax · 11534395 · Formulation · US
- — Lotemax · 10596107 · Formulation · US
Sponsor landscape (corticosteroid class)
- Kala Pharmaceuticals, Inc. · 2 drugs in this class
- Balmoral Medical company · 1 drug in this class
- Bausch & Lomb Incorporated · 1 drug in this class
- Cerium Pharmaceuticals, Inc. · 1 drug in this class
- Dr. Reddys Laboratories, SA · 1 drug in this class
- Edesa Biotech Inc. · 1 drug in this class
- Evon Medics LLC · 1 drug in this class
- Federal University of São Paulo · 1 drug in this class
- Khon Kaen University · 1 drug in this class
- LEO Pharma · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Vehicle of Ophthalmic Loteprednol Etabonate CI watch — RSS
- Vehicle of Ophthalmic Loteprednol Etabonate CI watch — Atom
- Vehicle of Ophthalmic Loteprednol Etabonate CI watch — JSON
- Vehicle of Ophthalmic Loteprednol Etabonate alone — RSS
- Whole corticosteroid class — RSS
Cite this brief
Drug Landscape (2026). Vehicle of Ophthalmic Loteprednol Etabonate — Competitive Intelligence Brief. https://druglandscape.com/ci/vehicle-of-ophthalmic-loteprednol-etabonate. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab